WO2019203813A1 - Compositions contenant des tétrahydrocurcuminoïdes pour l'amélioration de la santé et de l'hygiène buccales - Google Patents
Compositions contenant des tétrahydrocurcuminoïdes pour l'amélioration de la santé et de l'hygiène buccales Download PDFInfo
- Publication number
- WO2019203813A1 WO2019203813A1 PCT/US2018/028077 US2018028077W WO2019203813A1 WO 2019203813 A1 WO2019203813 A1 WO 2019203813A1 US 2018028077 W US2018028077 W US 2018028077W WO 2019203813 A1 WO2019203813 A1 WO 2019203813A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablets
- candies
- gingivitis
- lotions
- ointments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- the present invention relates to a novel composition containing tetrahydroeurcuminoids for die improvement of oral health and hygiene. More specifically, the invention relates to a novel tetrahydrocurcuminoid composition and its application in therapeutic management of canker sore mid gingivitis.
- the health and hygiene of the teeth, the mouth, and mucosal tracts of the oral cavity is important to a person's overall health-
- the common type of oral disease include dental cavities, caries, bad breath and gum diseases, including canker sore, gingivitis, and periodontitis.
- RAS Recurrent aphthous stomatitis
- canker sores is one of the most common, painful oral ailments, characterized by multiple, small, round, or ovoid ulcers with circumscribed margins, erythematous haloes, and yellow or grey floors that presents itself in childhood or adolescence.
- Scully C Porter S. Oral mucosal disease: recurrent aphthous stomatitis, Br J Oral Maxillofac Surg. 2008 Apr;46(3): 198-206; Preeti L, et al., Recurrent aphthous stomatitis, J Oral Maxillofac
- Gingivitis affects an estimated 80% of the population and is the world's most predominant inflammatory periodontal disease. The disease is initiated with a pathogenic biofilm, or plaque, around the teeth followed by a host immune-inflammatory response that advances the disease.
- the principle objective of the invention is to disclose a composition containing tetrahydrocurcuminoids and for the improvement of oral health and hygiene.
- the present invention discloses a composition containing tetrahydrocurcuminoids for the improvement of oral health and hygiene. Specifically the invention discloses a novel composition of tetrahydrocurcuminoids for the therapeutic management of canker sore and gingivitis.
- Fig,la shows graphical representation of median VAS seme at three time points; p value ⁇ 0.001 using Friedman ANNOV A,
- Fig, lb shows graphical representation of median throat relief score at three points
- Fig. lc shows graphical representation of distribution of patients as per throat numbness at different time points
- Fig. 2a and 2b shows Line plots mean values of different LOE & SILNESS Index parameters ami total points at three times in Gingivitis group
- the invention relates to a novel composition containing tetrahydrocurcuminoids for the improvement of oral health and hygiene.
- the composition contains tetrahydrocurcumin, teirahydrodemethoxycurcumin, tetrahydrobis-demethoxycurcumin, octahydrocurcuminoids and hexahydrocurcuminoids.
- the composition is formulated with pharmaceutically, nutraceuticaily and cosmeceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables.
- the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables are available separately or together in an oral health kit containing the said forms.
- the present invention discloses a method for therapeutic management of canker sore in mammals, said method comprising steps of administering an effective concentration of a composition containing tetrahydrocurcuminoids to mammals in need of such therapy, to bring about reduction in symptoms associated with canker sore.
- the symptoms of canker sore include, but not limited to. throat pain, ulcer, lesion, throat numbness, sore throat, bleeding, swelling at the site, reddening at the site, inflammation at the site, burning, swelling and paid in lymph node, difficulty in chewing and difficulty in swallowing.
- the composition is formulated with pharmaceutically, nutraceutically and cosmeceutically acceptable excipients, adjuvants, diluents of carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables hi a related embodiment, the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables, are available separately or together in an oral health kit containing the said forms.
- the mammal is preferably human.
- the present invention discloses a method for therapeutic management of gingivitis in mammals, said method comprising steps of administering an effective concentration of a composition containing tetrahydrocurcuminoids to mammals in need of such therapy, to bring about reduction in symptoms associated with gingivitis.
- the symptoms of gingivitis include, but not limited to, taste acceptability, burning sensation, dryness, soreness, ulcer, staining of teeth and tongue, and allergy.
- the composition is formulated with pharmaceutically, nutraceutically and cosmeceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables.
- the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables are available separately or together in an oral health kit containing the said forms.
- the mammal is preferably human. [Para0017] Specific illustrative examples enunciating the most preferred embodiments are included herein below.
- the sample size of the study was 60, with 30 subjects assigned to each of die two study arms in a manner there would be 30 subjects with canker sore and throat pain and 30 subjects with gingivitis. However, 31 subjects were enrolled for Canker Sore and 29 were enrolled for
- [ParaOQ32] AU enrolled subjects were instructed to self administer one chewable tablet (oral dosing) twice daily containing lOOmg of tetrahydrocurcuminoids for a period of 21 days.
- Table 1 Distribution of patients with different no of lesions across study visits.
- Example 3 Compositions / formulations containing tetrahydrocurcuminoids
- Tables 4-9 provide illustrative examples of nutraceutical formulations containing tetrahydrocurcuminoids for the management of canker sore and gingivitis [Para0059] Table 4: Tetrahydrocurcuminoids Chewable Tablet
- Table 10 and 11 provides illustrative examples for a mouth gel and mouth wash formulation containing tetrahydrocurcuminoids for the management of canker sore and gingivitis
- the invention also provides an illustrative example of an oral health kit comprising of formulation containing tetrahydracurcuminoids which include, but not limited to, the following: 1. Chewable tablets, candies and guinmies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
L'invention concerne une nouvelle composition contenant des tétrahydrocurcuminoïdes pour l'amélioration de la santé et de l'hygiène buccales. Plus spécifiquement, l'invention concerne une nouvelle composition de tétrahydrocurcuminoïdes et son application dans le traitement thérapeutique de l'aphte et de gingivites.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2018/028077 WO2019203813A1 (fr) | 2018-04-18 | 2018-04-18 | Compositions contenant des tétrahydrocurcuminoïdes pour l'amélioration de la santé et de l'hygiène buccales |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2018/028077 WO2019203813A1 (fr) | 2018-04-18 | 2018-04-18 | Compositions contenant des tétrahydrocurcuminoïdes pour l'amélioration de la santé et de l'hygiène buccales |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019203813A1 true WO2019203813A1 (fr) | 2019-10-24 |
Family
ID=68239733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/028077 WO2019203813A1 (fr) | 2018-04-18 | 2018-04-18 | Compositions contenant des tétrahydrocurcuminoïdes pour l'amélioration de la santé et de l'hygiène buccales |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019203813A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100034757A1 (en) * | 2006-11-24 | 2010-02-11 | Mitsukiyo Fujii | Extract powder of indigo plant, and its preparation and uses |
US8182843B2 (en) * | 2006-06-30 | 2012-05-22 | Piramal Life Sciences Limited | Herbal compositions for the treatment of diseases of the oral cavity |
US20140275271A1 (en) * | 2011-10-17 | 2014-09-18 | The Research Foundation For The State University Of New York | Novel modified curcumins and their uses |
US8916139B2 (en) * | 2010-04-09 | 2014-12-23 | Conopco, Inc. | Oral care compositions |
US20170319642A1 (en) * | 2014-10-27 | 2017-11-09 | Fbm Indústria Farmacêutica Ltda. | Soluble, stable, anti-inflammatory, proliferative, protective and mucoadhesive pharmaceutical compositions; use thereof for treating mucositis conditions and method for producing same; base pharmaceutical composition for preparing the pharmaceutical compositions and method for producing same |
-
2018
- 2018-04-18 WO PCT/US2018/028077 patent/WO2019203813A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8182843B2 (en) * | 2006-06-30 | 2012-05-22 | Piramal Life Sciences Limited | Herbal compositions for the treatment of diseases of the oral cavity |
US20100034757A1 (en) * | 2006-11-24 | 2010-02-11 | Mitsukiyo Fujii | Extract powder of indigo plant, and its preparation and uses |
US8916139B2 (en) * | 2010-04-09 | 2014-12-23 | Conopco, Inc. | Oral care compositions |
US20140275271A1 (en) * | 2011-10-17 | 2014-09-18 | The Research Foundation For The State University Of New York | Novel modified curcumins and their uses |
US20170319642A1 (en) * | 2014-10-27 | 2017-11-09 | Fbm Indústria Farmacêutica Ltda. | Soluble, stable, anti-inflammatory, proliferative, protective and mucoadhesive pharmaceutical compositions; use thereof for treating mucositis conditions and method for producing same; base pharmaceutical composition for preparing the pharmaceutical compositions and method for producing same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pai et al. | Evaluation of antiplaque activity of Azadirachta indica leaf extract gel—a 6-week clinical study | |
Wyatt | Elderly Canadians residing in long-term care hospitals: Part I. Medical and dental status | |
Sreenivasan et al. | Effects of a chlorhexidine mouthwash on clinical parameters of gingivitis, dental plaque and oral polymorphonuclear leukocytes [PMN] | |
Milligan et al. | Oral care for people with advanced cancer: an evidence-based protocol | |
JP2009513492A (ja) | 口腔アフタの治療用の組成物を製造するためのヒアルロン酸の使用 | |
Prakash et al. | Effect of punica granatum extract gel on gingival crevicular fluid levels of interleukin-1β, interleukin-8 and CCL28 levels: randomised controlled clinical trial | |
Roopa et al. | Curcumin: a herbal approach in the management of gingivitis | |
US20190321308A1 (en) | Compositions containing tetrahydrocurcuminoids for improvement of oral health and hygiene | |
Van Zyl et al. | Mouthwash: a review for South African health care workers: CPD | |
Thakare et al. | Genetic Mapping in Papillon‐Lefèvre Syndrome: A Report of Two Cases | |
WO2022200887A1 (fr) | Soin d'hygiène buccale liquide à base de coenzyme q10 naturelle multifonction ayant une efficacité antimicrobienne | |
WO2019203813A1 (fr) | Compositions contenant des tétrahydrocurcuminoïdes pour l'amélioration de la santé et de l'hygiène buccales | |
Milleman et al. | Subjective Assessment of Enamelon® Preventive Treatment Gel in a Self-Reported Dry-Mouth Population. | |
RU2605260C1 (ru) | Способ комплексного лечения больных с воспалительными заболеваниями пародонта | |
Garg et al. | Merits of oil pulling therapy in the management of xerostomia and stomatopyrosis in burning mouth syndrome | |
Singh et al. | Oral infections, a mirror of our overall health condition: An overview. | |
Gibson | Identifying and treating xerostomia in restorative patients | |
Abed et al. | Comparison between the effects of Aloe vera and chlorhexidine on clinical periodontal parameters | |
Agrawal et al. | Evaluation of clinical efficacy of Unani toothpowder (payorin) on plaque and gingivitis-A randomized clinical trial | |
Schmidt | Mouthwashes and gargles: oral health | |
Rajesh et al. | Effectiveness of chlorhexidine gel and ozonated oil in treatment of plaque induced gingivitis–a randomized controlled clinical study | |
Lewis et al. | Oral Ulceration | |
JAIN | Association of Dental Caries Based on Frequency of Tooth Brushing Habit-A Retrospective Study | |
Mane et al. | Clinical Evaluation Of Homeopathic Mouthwash Compared With Chlorhexidine (0.2%): A Randomized Controlled Study | |
LM et al. | Immune Mediated Sub-Epithelial Blistering Disorders: Case Series |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18915043 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18915043 Country of ref document: EP Kind code of ref document: A1 |